SCHEMBL30284630

SCHEMBL30284630

CN(C)Cc1cc(OCCCCCCCCCCCCC/C=C\C/C=C\CCCCCCCC(=O)O)cc(OCCCCCCCCCCCCC/C=C\C/C=C\CCCCCCCC(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.49
▸ PPARG P37231 7/20 0.49
▸ F7 P08709 6/20 0.49
▸ F3 P13726 6/20 0.49
▸ PPARD Q03181 6/20 0.49
▸ PPARA Q07869 6/20 0.49
▸ FFAR1 O14842 5/20 0.49
▸ CYP19A1 P11511 4/20 0.49
▸ MAPT P10636 4/20 0.49
▸ LMNA P02545 4/20 0.49
▸ ALOX15 P16050 4/20 0.49
▸ HSD17B10 Q99714 4/20 0.49
▸ PTGS1 P23219 3/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ CYP3A4 P08684 3/20 0.49
▸ HPGD P15428 3/20 0.49
▸ TDP1 Q9NUW8 3/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ RECQL P46063 3/20 0.49
▸ BLM P54132 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30457581 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL30849137 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL17685710 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL17685786 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL17685803 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL25431443 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL17685831 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL17685809 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL17685788 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD
SCHEMBL30284624 1.00 ALDH1A1 (0.49) ALDH1A1PPARGF7F3PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
EP-4452928-A1 CONSTRAINED LIPIDS AND METHODS OF USE THEREOF Renagade Therapeutics Management Inc. (US) 2024-10-30 — — EP disclosed
EP-4402123-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF Renagade Therapeutics Management Inc. (US) 2024-07-24 — — EP disclosed
WO-2024073848-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2024-04-11 — — WO disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 — — WO disclosed
WO-2023196931-A1 CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-12 — — WO disclosed
WO-2023137550-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2023-07-27 — — WO disclosed
WO-2023122752-A1 CONSTRAINED LIPIDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-06-29 — — WO disclosed
WO-2023050003-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2023-04-06 — — WO disclosed
WO-2023044333-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-03-23 — — WO disclosed
WO-2023023055-A1 COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-02-23 — — WO disclosed
Send feedback